Randomized phase II study of SGN-15 (CBR96-doxorubicin immunoconjugate) with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC).

@article{Ross2004RandomizedPI,
  title={Randomized phase II study of SGN-15 (CBR96-doxorubicin immunoconjugate) with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC).},
  author={H. Ross and C. Rudin and L. Hart and P. M. Swanson and M. Rarick and R. Figlin and A. D. Jacobs and D. Miller},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14_suppl},
  pages={7039}
}
  • H. Ross, C. Rudin, +5 authors D. Miller
  • Published 2004
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 7039 Background: Docetaxel (Doc) remains the only FDA approved second line chemotherapy for NSCLC, but response rates and survival are low. Targeted therapies may hold more promise. NSCLC cells express a variety of tumor antigens, including the Lewis Y (Ley) antigen. SGN-15 is a novel antibody-drug conjugate that targets Ley, and delivers doxorubicin intracellularly. A multi-center randomized phase II study was conducted to evaluate the safety and efficacy of the combination of SGN-15/Doc as… CONTINUE READING
    9 Citations
    Docetaxel in advanced non-small cell lung cancer
    • 5
    Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline
    • 87
    Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels
    • L. Krug, D. Milton, +11 authors C. Divgi
    • Medicine
    • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
    • 2007
    • 23
    Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies
    • 38
    Antibody conjugates and therapeutic strategies.
    • 42
    Making smart drugs smarter: The importance of linker chemistry in targeted drug delivery